التفاصيل البيبلوغرافية
| العنوان: |
Clinical impact of first‐line PD‐1 or PD‐L1 inhibitors combined with chemotherapy in extensive‐stage small cell lung cancer patients: A real‐world multicenter propensity score‐matched study. |
| المؤلفون: |
Xie, Jingyuan, Chen, Mo, Han, Hedong, Xu, Ke, Qiu, Guihuan, Lin, Xinqing, Song, Yong, Ye, Jinjun, Lv, Tangfeng, Zhan, Ping |
| المصدر: |
Thoracic Cancer; May2023, Vol. 14 Issue 15, p1327-1338, 12p |
| مصطلحات موضوعية: |
THERAPEUTIC use of antineoplastic agents, PROGRAMMED cell death 1 receptors, ETOPOSIDE, PLATINUM compounds, DRUG efficacy, RESEARCH, STATISTICS, KRUSKAL-Wallis Test, IMMUNE checkpoint inhibitors, PROGRAMMED death-ligand 1, CONFIDENCE intervals, SMALL cell carcinoma, CANCER chemotherapy, MULTIVARIATE analysis, SERUM, INFLAMMATION, LOG-rank test, LUNG tumors, RETROSPECTIVE studies, METASTASIS, CANCER patients, NEUTROPHIL lymphocyte ratio, RESEARCH funding, KAPLAN-Meier estimator, SURVIVAL analysis (Biometry), CHI-squared test, LACTATE dehydrogenase, TUMOR markers, PROGRESSION-free survival, LOGISTIC regression analysis, STATISTICAL models, DATA analysis software, IMMUNOTHERAPY, PROPORTIONAL hazards models, OVERALL survival, MONOCYTE lymphocyte ratio, CHEMICAL inhibitors, DISEASE risk factors |
| مصطلحات جغرافية: |
CHINA |
| مستخلص: |
Objectives: Our research aimed to evaluate the effectiveness of first‐line immune checkpoint inhibitors (ICIs) with etoposide and platinum (EP) for extensive‐stage small cell lung cancer (ES‐SCLC) and identify prognostic factors, as real‐world outcomes and the inconsistency of PD‐1 and PD‐L1 inhibitors are uncertain. Methods: We selected ES‐SCLC patients in three centers and conducted a propensity score‐matched analysis. The Kaplan–Meier method and Cox proportional hazards regression were conducted to compare the survival outcomes. We also performed univariate and multivariate Cox regression analyses to investigate predictors. Results: Among 236 patients included, 83 pairs of cases were matched. The EP plus ICIs cohort had a longer median overall survival (OS) (17.3 months) than the EP cohort (13.4 months) (hazard ratio [HR], 0.61 [0.45, 0.83]; p = 0.001). The median progression‐free survival (PFS) was also longer in the EP plus ICIs cohort (8.3 months) than in the EP cohort (5.9 months) (HR, 0.44 [0.32, 0.60]; p < 0.001). The EP plus ICIs group had a higher objective response rate (ORR) (EP: 62.3%, EP + ICIs: 84.3%, p < 0.001). Multivariate analysis presented that liver metastases (HR, 2.08; p = 0.018) and lymphocyte–monocyte ratio (LMR) (HR, 0.54; p = 0.049) were independent prognostic factors for OS, and performance status (PS) (HR, 2.11; p = 0.015), liver metastases (HR, 2.64; p = 0.002), and neutrophil‐lymphocyte ratio (NLR) (HR, 0.45; p = 0.028) were for PFS in patients with chemo‐immunotherapy. Conclusion: Our real‐world data demonstrated that ICIs with chemotherapy as the first‐line setting for ES‐SCLC are effective and safe. PS, liver metastases, and inflammatory markers could serve as valuable risk factors. [ABSTRACT FROM AUTHOR] |
|
Copyright of Thoracic Cancer is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder